Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. reports developments as a diagnostics solutions company focused on lung disease testing and biopharma development services. Its updates center on Diagnostic Tests such as Nodify Lung® Nodule Risk Assessment, Nodify CDT® and IQLung® Cancer Treatment Guidance, along with blood- and tissue-based testing, proteomic and genomic approaches, and development work for life sciences partners.
Recurring news also covers quarterly results, revenue guidance, test-volume trends, clinical validation studies, real-world evidence presentations at medical meetings, and the company’s efforts to expand evidence for lung nodule management and oncology testing applications.
Biodesix, a diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will present at the 42nd Annual William Blair Growth Stock Conference on June 8, 2022, at 9:20 a.m. CT in Chicago, IL. The company encourages investors to schedule meetings with management during the event. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. Biodesix specializes in comprehensive blood-based tests to assess lung disease risks, significantly enhancing patient care.
Biodesix, a data-driven diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The pre-recorded presentation will be available on-demand starting May 24 at 7:00 AM ET through the company's website. Biodesix specializes in non-invasive tests for lung diseases, utilizing multi-omics and AI technology. Their innovative tests, such as Nodify XL2 and IQLung, support critical decision-making in lung cancer treatment.
Biodesix, Inc. (BDSX) reveals clinical utility data for its Nodify XL2 Risk Assessment Test at the American Thoracic Society (ATS) 2022 Conference, held May 13-18 in San Francisco. The study shows that the test effectively reduces unnecessary imaging and procedures for lung nodules with a malignancy probability of ≤ 50%, presenting significant advantages in clinical management. Additionally, the ALTITUDE trial will be discussed, evaluating the clinical utility of the Nodify XL2. These presentations reinforce Biodesix's commitment to advancing lung disease diagnostics.
Biodesix (BDSX) announced Q1 2022 results with total revenue of $6.5 million, a 77% decrease year-over-year, influenced by lower COVID-19 diagnostic testing. However, core lung diagnostic revenue rose 17% to $4.6 million, driven by the Nodify test. The company added $27.4 million in debt and equity funding in Q2 2022, enhancing financial stability. Operating expenses increased 10% to $17.8 million, leading to a net loss of $15.6 million, a 124% increase. The outlook for 2022 remains positive, expecting total revenue between $37.5 and $39.5 million.
Biodesix (NASDAQ: BDSX) will announce its Q1 2022 financial results on May 11, 2022, before market open. A conference call will take place at 8:00 a.m. ET the same day, allowing management to discuss results and provide business updates. Biodesix specializes in diagnostic solutions for lung diseases, utilizing advanced AI technology.
The company has developed non-invasive tests addressing significant clinical questions, including the Nodify Lung® tests for risk assessment and the IQLung™ tests for treatment decisions in lung cancer patients.
Biodesix, Inc. (BDSX) announced a private placement of 6,508,376 common shares on April 7, 2022, raising approximately $11.7 million in net proceeds. These funds will support term loan repayment and general corporate purposes. The company also executed a Third Amendment to its 2021 Term Loan, providing additional financial flexibility. The repayment plan includes $3.0 million in April 2022 and another $2.0 million potentially extending to September 30, 2022. Biodesix reaffirms its 2022 revenue guidance of $37.5 million to $39.5 million.
Biodesix, Inc. (BDSX) has published new data validating the GeneStrat NGS test in the peer-reviewed journal, Diagnostics. This study confirms the efficacy of liquid biopsy tests for detecting tumor markers, contributing to lung cancer diagnostics. Biodesix will present findings on both the GeneStrat ddPCR and NGS tests at the AACR Annual Meeting from April 8-13, 2022. The combination of droplet digital PCR and NGS techniques enhances testing for non-small cell lung cancer (NSCLC), improving treatment options with rapid results.
Biodesix, Inc. (BDSX) reported its fourth-quarter and fiscal year 2021 results, showing lung diagnostic revenue of $5.4 million and $18.7 million, up 48% and 49% year-over-year. Total revenue reached $7.2 million for Q4 and $54.5 million for the year. The company doubled its sales force, which fueled growth. Despite the challenges of the pandemic, Biodesix plans to launch the GeneStrat NGS™ test in January 2022. However, net losses increased significantly, totaling $13.3 million for Q4 and $43.2 million for the year.
Biodesix, Inc. (Nasdaq: BDSX) has entered a purchase agreement with Lincoln Park Capital Fund, LLC to issue and sell up to $50 million of its common stock over a 36-month period. The agreement allows Biodesix to sell stock at its discretion, with no upper limit on purchase price based on market conditions. Proceeds will support growth initiatives and corporate purposes. The company retains the right to terminate the agreement without penalty, and there are no short-selling provisions involved.
Biodesix (NASDAQ: BDSX) presented critical data on its Primary Immune Response (PIR) test at the IASLC 2022 Lung Cancer Meeting. The PIR test categorizes patients into PIR-Not Resistant and PIR-Resistant, predicting responses to immune checkpoint inhibitors (ICIs). Results indicated that the test could forecast survival outcomes (HR=2.36, p=0.02 at baseline; HR=3.53, p=0.001 after ICI initiation) and identify those prone to rapid onset of immune-related adverse events (HR=2.40, p=0.08). The test is expected to commercially launch in 2023.